Cargando…

Systematic review and meta-analysis of temozolomide in animal models of glioma: was clinical efficacy predicted?

BACKGROUND: Malignant glioma is an aggressive tumour commonly associated with a dismal outcome despite optimal surgical and radio-chemotherapy. Since 2005 temozolomide has been established as first-line chemotherapy. We investigate the role of in vivo glioma models in predicting clinical efficacy. M...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirst, T C, Vesterinen, H M, Sena, E S, Egan, K J, Macleod, M R, Whittle, I R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553514/ https://www.ncbi.nlm.nih.gov/pubmed/23321511 http://dx.doi.org/10.1038/bjc.2012.504

Ejemplares similares

Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy
por: Guillevin, R, et al.
Publicado: (2011)

Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide
por: van Nifterik, K A, et al.
Publicado: (2010)

Temozolomide induces senescence but not apoptosis in human melanoma cells
por: Mhaidat, N M, et al.
Publicado: (2007)

Non-thermal atmospheric plasma induces ROS-independent cell death in U373MG glioma cells and augments the cytotoxicity of temozolomide
por: Conway, Gillian E, et al.
Publicado: (2016)

A systematic review and meta‐analysis of gene therapy in animal models of cerebral glioma: why did promise not translate to human therapy?
por: Hirst, T. C., et al.
Publicado: (2014)

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome
por: Hassel, J C, et al.
Publicado: (2010)

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma
por: Pedretti, M, et al.
Publicado: (2010)

Effect of alternative temozolomide schedules on glioblastoma O(6)-methylguanine-DNA methyltransferase activity and survival
por: Robinson, C G, et al.
Publicado: (2010)

O(6)-(4-bromothenyl)guanine reverses temozolomide resistance in human breast tumour MCF-7 cells and xenografts
por: Clemons, M, et al.
Publicado: (2005)

Activity of irinotecan and temozolomide in the presence of O(6)-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models
por: Cai, W, et al.
Publicado: (2010)

Temozolomide- and fotemustine-induced apoptosis in human malignant melanoma cells: response related to MGMT, MMR, DSBs, and p53
por: Naumann, S C, et al.
Publicado: (2009)

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
por: Daniel, R A, et al.
Publicado: (2010)

Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines
por: Mohammed, M Z, et al.
Publicado: (2011)

Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study
por: Martin, N K, et al.
Publicado: (2012)

Protein expression in experimental malignant glioma varies over time and is altered by radiotherapy treatment
por: Wibom, C, et al.
Publicado: (2006)

Lithium enhances the antitumour effect of temozolomide against TP53 wild-type glioblastoma cells via NFAT1/FasL signalling
por: Han, Sheng, et al.
Publicado: (2017)

Cell migration in paediatric glioma; characterisation and potential therapeutic targeting
por: Cockle, J V, et al.
Publicado: (2015)

Inhibition of telomerase activity in malignant glioma cells correlates with their sensitivity to temozolomide
por: Kanzawa, T, et al.
Publicado: (2003)

In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs
por: Ashley, D M, et al.
Publicado: (2008)

The neuro-steroid, 3β androstene 17α diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways
por: Graf, M R, et al.
Publicado: (2007)

Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1
por: Bertrand, Y, et al.
Publicado: (2011)

Inhibitory effects of pharmacological doses of melatonin on aromatase activity and expression in rat glioma cells
por: González, A, et al.
Publicado: (2007)

Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer
por: Rowland, A, et al.
Publicado: (2015)

Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids
por: Günther, W, et al.
Publicado: (2003)

Interactions between microenvironment and cancer cells in two animal models of bone metastasis
por: Blouin, S, et al.
Publicado: (2008)

TP53 regulates human AlkB homologue 2 expression in glioma resistance to Photofrin-mediated photodynamic therapy
por: Lee, S Y, et al.
Publicado: (2010)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas
por: Dufies, Maeva, et al.
Publicado: (2017)

Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel
por: Martinelli, M, et al.
Publicado: (2007)

Centrosome amplification induced by survivin suppression enhances both chromosome instability and radiosensitivity in glioma cells
por: Saito, T, et al.
Publicado: (2008)

Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts
por: Vlahovic, G, et al.
Publicado: (2007)

Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma
por: Arrieta, O, et al.
Publicado: (2005)

PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
por: Dredge, K, et al.
Publicado: (2011)

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value
por: Michlmayr, A, et al.
Publicado: (2010)

Photodynamic therapy augments the efficacy of oncolytic vaccinia virus against primary and metastatic tumours in mice
por: Gil, M, et al.
Publicado: (2011)

FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer
por: Marzi, L, et al.
Publicado: (2016)

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer
por: Fujita, T, et al.
Publicado: (2006)

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
por: Quintela-Fandino, M, et al.
Publicado: (2013)

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma
por: Fens, M H A M, et al.
Publicado: (2008)

Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic response
por: Venkatasubramanian, R, et al.
Publicado: (2010)

Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models
por: Cao, S, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0dkps5o7pllf4435ilmmj1jors